If you have obesity with related conditions like Type 2 diabetes, hypertension, sleep apnea, or cardiovascular disease, the health benefits of treatment extend well beyond weight loss
Incremental Increases: Following the initial phase, the dose is gradually increased every four weeks, under the guidance of your healthcare provider (e.g., to 0.5 mg, then 1.0 mg, and potentially up to 2.4 mg for weight management, as seen with Wegovy, or 2.0 mg for type 2 diabetes, as with Ozempic)
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum proteomic changes in normal adult subjects
[DOI] [PMC free article] [PubMed] [Google Scholar] (85).Tang X
This classification means they do not require FDA approval for safety or efficacy before marketing, and manufacturers cannot legally claim to diagnose, treat, cure, or prevent disease
MD, PhD1,2